Previous experiments demonstrated that CD4+/CD25+ T lymphocytes have a regulatory function on tumor-reactive cytotoxic T lymphocytes and thereby successfully suppress lymphocytic tumor rejection [41, 43]. The gene discussed is CD4; the disease is lymphoid neoplasm.